Table 1 Demographics and clinical features of patients at time of diagnosis
From: Mutational status predicts the risk of thromboembolic events in lung adenocarcinoma
Variable | EGFR (n = 104) | ALK (n = 52) | Unexposed group (n = 154) | Total (n = 310) | p-value |
|---|---|---|---|---|---|
Age mean ± SD | 66.9 ± 12.0 | 57.6 ± 11.9 | 67.4 ± 9.4 | 65.6 ± 11.3 | |
Gender: | NS | ||||
Female | 68 (65.4%) | 32 (61.5%) | 86 (55.8%) | 186 (60.0%) | |
Male | 36 (34.6%) | 20 (38.5%) | 68 (44.2%) | 124 (40.0%) | |
Stage: | <0.00 | ||||
I | 18 (17.3%) | 4 (7.7%) | 41 (26.6%) | 63 (20.3%) | 1 |
II | 8 (7.7%) | 1 (1.9%) | 24 (15.6%) | 33 (10.6%) | |
III | 7 (6.7%) | 13 (25.0%) | 35 (22.7%) | 55 (17.7%) | |
IV | 71 (68.3%) | 34 (65.4%) | 54 (35.1%) | 159 (51.3%) | |
Performance status: | NS | ||||
0 | 67 (64.4%) | 37 (71.1%) | 99 (64.3%) | 203 (65.5%) | |
1 | 33 (31.7%) | 12 (23.1%) | 46 (29.9%) | 91 (29.4%) | |
2 | 2 (1.9%) | 2 (3.8%) | 5 (3.2%) | 9 (2.9%) | |
3 | 2 (1.9%) | 1 (1.9%) | 4 (2.6%) | 7 (2.3%) | |
Smoking status: | <0.00 | ||||
Never-smoker | 45 (43.3%) | 26 (50.0%) | 15 (9.7%) | 86 (27.7%) | 1 |
Ex-smoker | 50 (48.1%) | 20 (38.5%) | 87 (56.5%) | 157 (50.6%) | |
Smoker | 9 (8.7%) | 6 (11.5%) | 52 (33.8%) | 67 (21.6%) | |
Diabetes | 7 (6.7%) | 2 (3.8%) | 15 (9.7%) | 24 (7.7%) | NS |
Hypertension | 31 (29.8%) | 11 (21.2%) | 64 (41.6%) | 106 (34.2%) | 0.014 |
AC before the event | 7 (6.7%) | 9 (17.3%) | 19 (12.3%) | 35 (11.3%) | NS |